Feb 11, 2025 Media Release Novartis bolsters late-stage cardiovascular pipeline with agreement to acquire Anthos Therapeutics for USD 925 million upfront Jan 31, 2025 Media Release Novartis continues strong momentum of sales growth with margin expansion, reaches key innovation milestones in 2024 ...
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases. No New Molecular Entity Yes Highest Development Phases Phase III Hyperlipoproteinaemia Most Recent Events 15 Jan 2025 Pelacarsen is still in phase-III clinical trials in Hyperlipopro...
The Phase IV (post-approval) clinical trials typically conducted by Medical Affairs now account for a considerably greater share of the clinical research investment for a drug tho in the past. Cardiovascular drugs, such as the Novartis product Diovan® Ivalsartan), are at the forefront of this...
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases. Yes - Malignant melanoma; Glioma; Thyroid cancer; Non-small cell lung cancer New Molecular EntityYes Highest Development Phases MarketedGlioma; Malignant melanoma; Non-small cell lung cancer...
莫里斯郡2021年12月22日 /美通社/ -- Novartis 今日宣布美國食品藥物管理局(FDA)核准 Leqvio® (inclisiran),這是第一個也是唯一一個小型干擾 RNA(siRNA)療法,用於降低低密度脂蛋白膽固醇(也稱為壞膽固醇或 LDL-C),在初始劑量和三個月後再給予一劑之後,每年僅需兩劑。
These are not all the possible side effects of Leqvio. Ask your health care provider for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. ...
Novartis withdraws EU approval request | Lilly launches clinical trials registry | FDA delays release of Critical Path Initiative | Antibody treatment for MS approved | Further warnings on antidepressants | Female testosterone patch rejected by advisory committee | Calcium-channel blocker benefits halts ...
Between 20% and 50% of PNH patients treated with Soliris or other drugs in the C5 inhibitor class can’t get symptoms under control and require blood transfusions, so there’s a clear need for new treatment options. The FDA approval is based on the APPLY-PNH and APPOINT-PNH trials, whic...
It's not a situation where a company has the opportunity to, in effect, walk away from the prices that are set by government. I'd also say, while in the short term this might be manageable on our first set of drugs, in the long run, this policy is really not good for innovation,...
there is no medication approved by the US Food and Drug Administration (FDA) for use in the treatment of this disorder. Accordingly, there is a need to identify therapeutic agents that can be used to treat it, in particular drugs that are effective on reducing gambling cravings, promoting abs...